Dipyridamole, >=98% (TLC), powder

Application

Dipyridamole has been used: to perform in vitro growth inhibition assay(40) to determine its ability to prevent uterine myometrial contractions(41) to determine its effects on nicotinamide adenine dinucleotide (NAD+)-induced increase in intracellular adenosine triphosphate (ATP) levels(42) to prevent nicotinamide riboside (NR)-induced axonal protection(43)

Biochem/physiol Actions

Selective inhibitor of phosphodiesterase V (PDE 5); potent coronary vasodilator drug; adenosine transport inhibitor; inhibitor of platelet aggregation.

Features and Benefits

This compound was developed by Boehringer Ingelheim. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is featured on the Phosphodiesterases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

General description

Dipyridamole prevents cellular uptake of adenosine. It functions as an equilibrative nucleoside transporter 1 (ENT1) inhibitor.

Packaging

1, 5, 10, 25 g in glass bottle